The management of rheumatoid arthritis (RA) during the peri-conceptional period necessitates consideration of maternal disease control and its impact on fetal growth, as well as the administration of vaccinations to both mothers and infants. Currently, only tumor necrosis factor-α (TNF-α) inhibitors possess adequate empirical evidence supporting their safety during preconception and lactation periods. Discontinuation of Fc structural domain-containing TNF-α inhibitors is required in the third trimester, only certolizumab pegol stands out as a viable option throughout pregnancy. The available research data on other biological agents for RA remains insufficient to establish their safety in pregnancy. The impact of biological agents on vaccination and vaccine response, especially for live attenuated vaccines, should be considered in both mothers and infants.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |